Company intelligence / Profile preview

Psicofarma

Mexico City, Mexico City, Mexico

Ownership: Private
Employees: ~528
Development stage: Other

Overview

Psicofarma has the leading neuropsychiatric drug portfolio and prescription volume in Mexico, with continued double-digit growth over recent years. The company has developed both generic and proprietary medicines, including combination drugs and, more recently, oncology candidates in collaboration with academic institutions. It exports to Latin America and has FDA-approved products in clinical trials as orphan drugs, with further plans to expand into Europe and the US market.[1][2][3]

Therapeutic areas: OncologyNeurologyPsychiatry
Modalities: Small moleculeBiologicProbioticOver-the-counter product
Industry: Biotech

Partnerships

UNAM (Universidad Nacional Autónoma de México)Indian biotechnology companies (for joint venture biomanufacturing)Puerto Rico-based research partners

Beyond the preview

Go deeper on Psicofarma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Psicofarma.

Explore the full profile